Literature DB >> 18453623

Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice.

Michelle R Simpson-Abelson1, Gregory F Sonnenberg, Hiroshi Takita, Sandra J Yokota, Thomas F Conway, Raymond J Kelleher, Leonard D Shultz, Maurice Barcos, Richard B Bankert.   

Abstract

Non-disrupted pieces of primary human lung tumor implanted into NOD-scid IL2Rgamma(null) mice consistently result in successful xenografts in which tissue architecture, including tumor-associated leukocytes, stromal fibroblasts, and tumor cells are preserved for prolonged periods with limited host-vs-graft interference. Human CD45(+) tumor-associated leukocytes within the xenograft are predominantly CD3(+) T cells with fewer CD138(+) plasma cells. The effector memory T cells that had been shown to be quiescent in human lung tumor microenvironments can be activated in situ as determined by the production of human IFN-gamma in response to exogenous IL-12. Plasma cells remain functional as evidenced by production of human Ig. Significant levels of human IFN-gamma and Ig were detected in sera from xenograft-bearing mice for up to 9 wk postengraftment. Tumor-associated T cells were found to migrate from the microenvironment of the xenograft to the lung, liver, and primarily the spleen. At 8 wk postengraftment, a significant portion of cells isolated from the mouse spleens were found to be human CD45(+) cells. The majority of CD45(+) cells were CD3(+) and expressed a phenotype consistent with an effector memory T cell, consisting of CD4(+) or CD8(+) T cells that were CD45RO(+), CD44(+), CD62L(-), and CD25(-). Following adoptive transfer into non-tumor bearing NOD-scid IL2Rgamma(null) mice, these human T cells were found to expand in the spleen, produce IFN-gamma, and maintain an effector memory phenotype. We conclude that the NOD-scid IL2Rgamma(null) tumor xenograft model provides an opportunity to study tumor and tumor-stromal cell interactions in situ for prolonged periods.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18453623     DOI: 10.4049/jimmunol.180.10.7009

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  51 in total

1.  Human nasal polyp microenvironments maintained in a viable and functional state as xenografts in NOD-scid IL2rgamma(null) mice.

Authors:  Joel M Bernstein; Stephen P Brooks; Heather K Lehman; Liza Pope; Amy Sands; Leonard D Shultz; Richard B Bankert
Journal:  Ann Otol Rhinol Laryngol       Date:  2009-12       Impact factor: 1.547

Review 2.  Humanized mice for immune checkpoint blockade in human solid tumors.

Authors:  Henry Yip; Carl Haupt; Grace Maresh; Xin Zhang; Li Li
Journal:  Am J Clin Exp Urol       Date:  2019-10-15

Review 3.  Human cancer growth and therapy in immunodeficient mouse models.

Authors:  Leonard D Shultz; Neal Goodwin; Fumihiko Ishikawa; Vishnu Hosur; Bonnie L Lyons; Dale L Greiner
Journal:  Cold Spring Harb Protoc       Date:  2014-07-01

4.  T cells and stromal fibroblasts in human tumor microenvironments represent potential therapeutic targets.

Authors:  Jennifer L Barnas; Michelle R Simpson-Abelson; Sandra J Yokota; Raymond J Kelleher; Richard B Bankert
Journal:  Cancer Microenviron       Date:  2010-03-31

Review 5.  Prioritizing therapeutic targets using patient-derived xenograft models.

Authors:  K A Lodhia; A M Hadley; P Haluska; C L Scott
Journal:  Biochim Biophys Acta       Date:  2015-03-14

Review 6.  Humanized mice for immune system investigation: progress, promise and challenges.

Authors:  Leonard D Shultz; Michael A Brehm; J Victor Garcia-Martinez; Dale L Greiner
Journal:  Nat Rev Immunol       Date:  2012-10-12       Impact factor: 53.106

7.  Patient-derived xenografts of low-grade B-cell lymphomas demonstrate roles of the tumor microenvironment.

Authors:  W Richard Burack; Janice M Spence; John P Spence; Stephen A Spence; Philip J Rock; Gautam N Shenoy; Leonard D Shultz; Richard B Bankert; Steven H Bernstein
Journal:  Blood Adv       Date:  2017-07-07

8.  Tumor characteristics associated with engraftment of patient-derived non-small cell lung cancer xenografts in immunocompromised mice.

Authors:  Yungchang Chen; Ran Zhang; Li Wang; Arlene M Correa; Apar Pataer; Yi Xu; Xiaoshan Zhang; Chenghui Ren; Shuhong Wu; Qing H Meng; Junya Fujimoto; Vanessa B Jensen; Mara B Antonoff; Wayne L Hofstetter; Reza J Mehran; George Pisimisis; David C Rice; Boris Sepesi; Ara A Vaporciyan; Garrett L Walsh; Stephen G Swisher; Jack A Roth; John V Heymach; Bingliang Fang
Journal:  Cancer       Date:  2019-07-09       Impact factor: 6.860

Review 9.  Use of humanized severe combined immunodeficient mice for human vaccine development.

Authors:  Gloria C Koo; Aisha Hasan; Richard J O'Reilly
Journal:  Expert Rev Vaccines       Date:  2009-01       Impact factor: 5.217

10.  IL-12 delivered intratumorally by multilamellar liposomes reactivates memory T cells in human tumor microenvironments.

Authors:  Michelle R Simpson-Abelson; Vivek S Purohit; Wing Man Pang; Vandana Iyer; Kunle Odunsi; Todd L Demmy; Sandra J Yokota; Jenni L Loyall; Raymond J Kelleher; Sathy Balu-Iyer; Richard B Bankert
Journal:  Clin Immunol       Date:  2009-04-22       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.